Genzyme Corporate Research Search Genzyme Websites
Patients and FamiliesHealth Care ProfessionalsAbout Genzyme Therapeutics
Fabry Community HomeFabry Community
Health Care Professional Overview
About Fabry Disease
Signs and Symptoms
Genetics of Fabry Disease
Diagnosing Fabry
Disease Monograph
Current Treatments
The Fabry Registry
Genzyme Support
Resources

Gastrointestinal Manifestations

Renal ImpactCardiac Dysfunction
Cerebrovascular ComplicationsPain
AngiokeratomasHypohidrosis/Anhidrosis
Ophthalmologic FindingsHeat and Cold Intolerance
Gastrointestinal Manifestations 

Gastrointestinal symptoms are thought to be due to the deposition of glycosphingolipids in mesenteric blood vessels and autonomic ganglia.[1] Up to two thirds of affected males and about half of symptomatic female carriers may experience gastrointestinal symptoms associated with Fabry disease.[2,3] Gastrointestinal symptoms may include:[4]

  • Postprandial bloating
  • Abdominal cramping and pain
  • Early satiety
  • Diarrhea
  • Constipation
  • Nausea
  • Vomiting

References

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001;3733-3774.

2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-760.

3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.

4. Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun. 1998;19:887-891.

Keyword: 
Search In: 
New Page 1
Fabry Voices
""

More Fabry patient profiles
Resources
Medical Information Services
Request Materials
Publications
Events Calendar
Related Links
Fabry Registry

First Symptoms to Diagnosis

Data from the Fabry Registry confirms the large gap between the average age of symptoms onset (10.5) and diagnosis of Fabry disease (28.5). To learn more about the importance of the Fabry Registry click here.

Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142
617 768 9000
800 745 4447

Genzyme Europe BV
Gooimeer 10
1411 DD Naarden
The Netherlands
31 35 699 1200
Contact Genzyme


Terms and Conditions of Use | Privacy Policy | © 2003-2009 Genzyme Corporation. All rights reserved.| © Fabr/US/P219/08/05
Genzyme Therapeutics